Health Care·Biotechnology·$3.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.14 | N/A | +47.37% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.14 | N/A | +47.37% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the earnings performance despite not providing specific revenue figures. They emphasized their commitment to strategic goals.
We are pleased with our EPS performance this quarter.
Our focus remains on executing our strategic initiatives.
Catalyst Pharmaceuticals reported a strong EPS performance, exceeding expectations significantly. However, the stock fell by 1.75% on the day, likely due to the lack of revenue details and guidance. Investors may be cautious as they await more comprehensive financial insights in future reports.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
US FOODS HLDG CORP
Nov 8, 2021